Sobi acquires CTI BioPharma and its JAK inhibitor for $1.7B.
TL;DR Summary
Swedish pharma company Sobi is acquiring CTI BioPharma for $1.7 billion, with the main attraction being the JAK inhibitor Vonjo, which received FDA accelerated approval last year for a rare bone marrow cancer. Sobi is paying an 89% premium to CTI's closing stock price on Tuesday. Sobi specializes in rare diseases.
- Sobi to acquire CTI BioPharma and its approved JAK inhibitor for $1.7B – Endpoints News Endpoints News
- CTI BioPharma Stock Soars on Deal to Be Acquired for $1.7 Billion Barron's
- Sweden’s Sobi to Buy CTI Biopharma for $1.7 Billion Yahoo Finance
- In $1.7B buy, Sobi acquires CTI and myelofibrosis drug Vonjo FiercePharma
- CTI BioPharma soars on deal news, while Upstart and Rivian climb after earnings MarketWatch
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
6 min
vs 7 min read
Condensed
96%
1,301 → 51 words
Want the full story? Read the original article
Read on Endpoints News